These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10965496)

  • 21. Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.
    Mariatos G; Gorgoulis VG; Zacharatos P; Kotsinas A; Vogiatzi T; Rassidakis G; Foukas P; Liloglou T; Tiniakos D; Angelou N; Manolis EN; Veslemes M; Field JK; Kittas C
    Int J Cancer; 2000 Mar; 89(2):133-41. PubMed ID: 10754490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
    Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T
    Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
    Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
    Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of MdmX on Mdm2-mediated downregulation of pRB.
    Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
    FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus.
    Guenova M; Rassidakis GZ; Gorgoulis VG; Angelopoulou MK; Siakantaris MR; Kanavaros P; Pangalis GA; Kittas C
    Mod Pathol; 1999 Nov; 12(11):1062-71. PubMed ID: 10574604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
    Sano T; Hikino T; Xue Q; Saito T; Kashiwabara K; Oyama T; Nakajima T
    Pathol Int; 2000 Sep; 50(9):709-16. PubMed ID: 11012984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.
    Masuya D; Huang C; Liu D; Nakashima T; Yokomise H; Ueno M; Nakashima N; Sumitomo S
    J Pathol; 2006 Apr; 208(5):724-32. PubMed ID: 16450335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner.
    Miwa S; Uchida C; Kitagawa K; Hattori T; Oda T; Sugimura H; Yasuda H; Nakamura H; Chida K; Kitagawa M
    Biochem Biophys Res Commun; 2006 Feb; 340(1):54-61. PubMed ID: 16343421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
    Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
    Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
    Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
    Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
    Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
    Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
    Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
    Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
    Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.